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Purpose/Objective: To evaluate the appropriateness of SBRT in pts 
with T1-2 lung cancer diagnosed with only CT-PET imaging. 
Materials and Methods: Between September 2009 and August 2012, 37 
T1-2 lung cancer pts underwent SBRT with Helical Tomotherapy . 17 
of the 37 pts had biopsy proven malignancy while in the remaining 20 
pts diagnosis was only based on CTPET imaging because they were 
unfit for any invasive procedure. Pts were treated with 60Gy/6fx, 
52Gy/4fx, 50Gy/5fx or 48Gy/4fx according to nodule diameter and 
location inside the chest. 
Results: 33/37 pts were eligible for evaluation; they have a minimum 
follow up of 3 mns. Median follow up was 12 mns (range 3-33). Of 
these 33 pts, 17 (group A) had had biopsy while 16 (group B) had 
CTPET-based diagnosis of malignancy. Pts in group A were staged as 
follows: 12 pts T1 and 4 T2 and there were 3 NSCLC nos, 11 adenoca 
and scc. In group A 6 pts (35.3%) and 5 pts (29.4%) had local and 
distant relapse, respectively. In pts in group B there were 4 (25%) and 
3 (18.7%) local and distant relapses. There were no statistical 
difference in local or distant relapse between the 2 groups. 
Conclusions: Despite the small number of pts considered, the two 
groups showed no difference in outcome and this evidence could 
suggest that CTPET may be a reliable tool to select pts unfit for 
invasive diagnostic procedures for SBRT.  
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Purpose/Objective: The treatment of moving lesions is one of the 
most important problems in radiotherapy. In the case of conventional 
radiotherapy treatment planning 15-20 mm margin from the edge of 
the clinical target volume (CTV) is applied. It significantly increases 
an irradiated volume that leads to the risk of the radiation-induced 
toxicity. One of the effective ways to minimize absorbed dose in 
normal tissue is the usage of breath-holding techniques. This study 
provides the utilization efficiency estimation of active breathing 
control (ABC) for radiotherapy of moving targets such as lesions in 
lung and liver. 
Materials and Methods: Thirty-five patients were treated in the 
Centre for Stereotactic Radiotherapy and Radiosurgery in Novosibirsk 
Research Institute for Circulation Pathology by stereotactic 
radiotherapy (SBRT) with breath-holding at inhale. Twenty-one 
patients had primary lung malignant lesions, pulmonary metastases 
were in nine cases, and five patients had a liver metastatic tumors. 
The 2 mm-thick slices CT simulation scans were performed with the 
intravascular contrast during breath-holding. The clinical target 
volume (CTV) included the gross target volume (GTV) plus 3-5 mm 
margin. For each fraction all patients received pre- and post-
treatment cone beam CT scans with ABC. 
Results: All patients completed the prescribed radiotherapy 
treatment with ABC. Because of ABC usage, margin from the clinical 
target volume (CTV) to the planning target volume (PTV) was 
significantly reduced up to 7±3 mm. The average breath-holding time 
was 18 sec. ABC allows to significantly increase of the total delivered 
dose. For lung primary tumors the mean dose was 74±4 Gr with 2 Gr 
per fraction, or 54 Gr in 3 fractions for SBRT cases; for pulmonary 
metastasis 20 Gr in one fraction was prescribed; for liver metastasis 
the dose was 45 Gr in three fractions. The intermediate results 
showed no signs of disease progression in 66% of the cases. 15% of the 
cases had a partial reduction. There was a disease progression 
requiring polychemotherapy in 14% of the cases. For 5% of the 
patients, the size of the lesion remained the same. 
Conclusions: The radiotherapy treatment of the moving lesions with 
ABC at inhale is an effective method to reduce organ motion during 
treatment. Thereafter, the procedure requires smaller PTV margins 
and allows to minimize the absorbed dose to the normal tissues as 
well as the risk of radiation-induced toxicity.  
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Purpose/Objective: The impact of radiation therapy (RT) and the 
optimal techniques in the trimodal treatment concepts of malignant 
pleural mesothelioma (MPM) are subject of current investigations. 
Based on our previous report that demonstrated improved dose 
coverage by using IMRT in comparison to 3D-conformal RT (3D-CRT) 
(Krayenbuehl et al. IJROBP 2007) we have now reviewed the clinical 
outcome with IMRT after neoadjuvant chemotherapy and extrapleural 
pneumonectomy (EPP). 
Materials and Methods: From 2005 to 2011 fourteen patients with 
stage 1-3 MPM were treated in a curative intent with adjuvant IMRT, 3 
cycles of neoadjuvant chemotherapy and EPP. IMRT was planned on 
Eclipse (Varian Medical System) using 5-7 coplanar beams to a total 
median dose of 56 Gy (54-60 Gy) with an integrated simultaneous 
boost to the high risk area in 12 patients or in 2 phases in 2 patients. 
We evaluated the locoregional recurrence, disease free survival and 
overall survival for 14 IMRT patients and 25 3D-CRT patients. The 
latter were treated in the pre IMRT era between 1999 and 2005. Local 
recurrence was defined as relapse in the radiation field or at the field 
border. A matched-pair analysis was performed on 11 patients in each 
group. 
Results: The median age at diagnosis was 61 years (46-72) and the 
median follow up was 15.5 ± 15.7 months for the IMRT group and 13.6 
± 9.2 months for the 3D-CRT group.  
For patients included in the matched-pair analysis, the local control 
was 73% vs. 27% in IMRT vs. 3D-CRT treated patients (p=0.06). The 
median time to local relapse after IMRT was 15.6 ± 3.3 months and 
11.0 ± 5.5 months after 3D-CRT (p=0.31). The median overall survival 
and disease free survival after IMRT and 3D-CRT were 22.4 ± 16.2 vs. 
21.5 ± 9.3 months (p=0.57) and 17.3 ± 12.3 vs. 11.4 ± 8.6 months (p = 
0.72). Taking into account all patients 4 IMRT treated patients (28.6 
%) and 12 patients in the 3D-CRT-group (48%) had local failure. In the 
IMRT (respectively 3D-CRT) groups 71.4% (resp. 80%) had distant 
recurrences (p=0.70). 
Conclusions: Our data indicates that the use of IMRT might improve 
local control, time to local relapse and disease free survival after EPP 
but has little impact on distant recurrence and overall survival. 
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Purpose/Objective: To analyze the dosimetric differences between 
the conventional conformal radiation therapy (CR) and the volumetric 
modulated arc therapy (VMAT) for locally advanced non-small-cell 
lung cancer (NSCLC). 
Materials and Methods: Two plans (CR and VMAT) were calculated for 
ten patients with locally advanced NSCLC. Both treatment plans were 
generated by 'Eclipse' (Varian, CA) for a linear accelerator 'Trilogy' 
with heterogeneity correction (Analytical Anisotropic Algorithm). Sixty 
six Gy in 33 fractions was prescribed in both cases. Four to five 6 MV 
photon beams were used for the CR and two arc with 6 MV beam for 
the VMAT. Dose to PTV, organs at risk and external contours (body), 
conformity index (PTV volume/volume of the 95% reference isodose) 
and homogeneity index ([maximal dose - minimaldose]/dose 
prescription) were compared.  
Results: Doses delivered to PTV (homogeneity index, maximal,minimal 
and mean dose) are similar with both techniques but conformity index 
is improved by 60% with VMAT: from 0.55 ± 0.07 with CR to 0.89 ± 
0.07 with VMAT (P = 0.002). Pulmonary protection is improved with 
VMAT: with CR and VMAT, respectively, the mean lung dose is 14.1 ± 
5.2 Gy and 12.2 ± 4.5 Gy, the lung volume which receives at least 
30Gy (V30) is 20±8% and14±5%, and the V20 is 24±11% and 20±10% 
(P=0.002). The mean dose received by the body is also 9% lower (P = 
0.004) and V5 is 13% higher (P = 0.004) with VMAT. V10 and V15 were 
similar with both modalities. From 20 Gy and higher, irradiated body 
volume is larger with CR than with VMAT. The relative difference 
increases with the dose: from 10% for 20 Gy (P = 0.014) up to 39% for 
62.7 Gy (P =0.002).  
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Conclusions: Compared to CR, VMAT greatly improves conformity and 
reduces mean dose and dose delivered from 20 Gy and higher to the 
lungs and the body.These results led us to plan a new dosimetric 
comparison between VMAT and Helical Tomotherapy. This will be the 
subject of a forthcoming study. 
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Purpose/Objective: To evaluate feasibility, early results and toxicity 
profile of post-operative whole breast irradiation after conserving 
surgery for early breast cancer (EBC) delivered with TomoDirect (TD), 
static angles Tomotherapy, within an accelerated hypofractionated 
(HF) schedule employing a simultaneous integrated boost (SIB) to the 
surgical bed. We herein present early results of a prospective phase II 
trial, undergoing at Ospedale Regionale ‘U. Parini’, AUSL valle 
d’Aosta, Aosta (Italy)  
Materials and Methods: Between June 2011 and June 2012 a total of 
52 consecutive EBC patients have been treated with HF TD at our 
Department. Histologically proven left- and right-sided breast 
adenocarcinoma, pathologically staged pTis/pT1/pT2, pN0-N1 after 
lumpectomy/quadrantectomy, were included (eventual association 
with hormonal therapy, chemotherapy and trastuzumab) . Patients 
were prescribed 45 Gy/20 fractions to the whole breast with a 
concomitant delivery of a SIB dose to the lumpectomy cavity of 0.25 
Gy daily up to 5 adjunctive Gy (total nominal dose of 50 Gy/20 fr 2.5 
Gy daily), employing the TD system. The 95% percentage PTV volume 
should be covered at least by 95% of the prescribed dose. The PTV was 
restricted to <53.5 Gy at 3% volume. Considered organs at risk for 
dosimetric constraints were lungs, heart and contralateral breast. TD 
beam arrangement consisted of 4 to 6 fields according to patients 
characteristics and consequent dose distribution. Acute toxicity was 
scored according to RTOG scale, chronic toxicity according to LENT-
SOMA scale, cosmesis was evaluated according to Harvard criteria and 
quality of life employing EORTC QLQ-C30 and QLQ-BR23 
questionnaires. 
Results: All patients completed the planned radiotherapy program 
with no clinical-related treatment interruptions. Radiation therapy 
was generally well tolerated; 42 patients (81%) had G0-G1 skin 
toxicity, while 10 patients experienced RTOG G2 erythema (19%); no 
grade 3 toxicities were reported. Up to 30 patients achieved a 
minimal follow-up time of 6 months; among them mild skin late 
effects were observed (mainly hyperpigmentation; 4% LENT-SOMA G1). 
Skin cosmesis was judged optimal/good in almost all of these patients 
(98%). Quality of life was generally good (both globally with QLQC-30 
and specifically with QLQ-BR23).As expected no local or systemic 
relapse were detected. 
Conclusions: TD has demonstrated to be a feasible and efficient mean 
to deliver accelerated hypofractionated adjuvant radiation in EBC 
patients after conserving surgery, with an optimal dose distribution, 
negligible toxicity and encouraging clinical results. This technical 
solution is a valid IMRT option for breast radiation treatment. 
   
EP-1040   
Dosimetric comparison of 3DCRT, IMRT and Carotid sparing IMRT in 
breast cancer patients 
P. Erpolat1, M. Akmansu1, S. Catli1, K. Akkan2, H. Bora1 
1Gazi Üniv. Tip Fakültesi, Radiation Oncology, Ankara, Turkey  
2Gazi Üniv. Tip Fakültesi, Radiology, Ankara, Turkey  
 
Purpose/Objective: The proximal carotid artery is often included 
within a supraclavicular RT field in patients with node-positive 
disease. It is rational that these patients have a greater risk of 
cerebrovascular events, which has been shown after head and neck 
irradiation. The purpose of our study was to determine the radiation 
doses to carotid artery among three dimensional conformal 
radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) 
and to perform carotid sparing intensity modulated radiotherapy (CS-
IMRT) without compromising target volume coverage. 
Materials and Methods: Ten patients who were treated with 
comprehensive 3DCRT were selected. DICOM data were used to create 
virtual IMRT and CS-IMRT plans. The carotid artery was retrospectively 
contoured. The inverse planning for IMRT was constituted and 5-field 
beam arrangement was used. The optimization objectives of the CTV, 
PTV and organ at risks were defined as used for 3DCRT. The dose 
constraints for organ at risk were as follows: V20<20% for ipsilateral 
lung; V30<10% for heart;V10 for contralateral lung; V10 for 
contralateral breast; 50 Gy for ipsilateral brachial plexus. For CS-
IMRT, V35 for ipsilateral carotid artery was additionally defined. The 
prescription dose was 50 Gy at 2 Gy per fraction for three planning. 
≥95% of the PTV received 100% of the prescription dose. The 
parameters used for comparison of planning were V20 for ipsilateral 
lung; V30 for heart, V10 for contralateral lung; V10 for contralateral 
breast,mean, and median maximum dose along with V35 and V50 for 
carotid artery. 
Results: There was a difference in terms of HI and CI among the three 
treatment plans. After pairwise comparison; 3DCRT plans had greater 
HI and had less CI than IMRT and CS-IMRT planings.3DCRT plans had 
significantly higher percentages of V20 ipsilateral lung volume and had 
significantly lower percentages of V10 contralateral lung volume 
compared to IMRT and CS-IMRT planings. Although no difference for 
V20 ipsilateral lung was observed between IMRT plans, the percentage 
of V10 contralateral lung was lower in the CS-IMRT plans compared to 
IMRT plans.  Carotid artery doses were significantly increased with 
IMRT compared to 3DCRT plans. With 3DCRT planning, V35 and V50 
were 57.5% and 12.65%. With IMRT planning, V35 and V50 were 
increased to 63.5%and 44% (p<0.005). After application of dose 
constraints to the carotid arteries, these parameters were found as 
61% and 0% in CS-IMRT planning without compromising target volume 
coverage. The results of dose parameters for planning were 
summarized in Table 1. 
 
 
